Related Experiment Videos
Increased expression of cyclooxygenase-2 protein in human gastric carcinoma
1Department of Hematology and Oncology, Ajou University School of Medicine, Suwon, Korea. Hoyeong@unitel.co.kr
Abstract:
Gastric adenocarcinoma is one of the most common malignancies in the world, and yet little is known about its molecular process of development and progression. Recent studies have suggested that ingestion of nonsteroid anti-inflammatory drugs reduces the risk of colon cancer, presumably by inhibiting the cyclooxygenase (COX) enzyme. COX-2, one isoform of the COX enzyme, is the rate-limiting enzyme in prostaglandin synthesis, and the function of this enzyme is thought to relate to inflammatory processes and carcinogenesis. To understand the role of COX enzyme in gastric cancer, we measured COX-2 expression in 104 human gastric carcinoma tissues by immunohistochemical analysis. We obtained tissue specimens from 104 surgically resected gastric adenocarcinoma patients. We performed immunohistochemical stain for human COX-2 with polyclonal antibody in gastric carcinoma. After curative resection and extensive lymph node dissection, all patients received adjuvant chemotherapy containing 5-fluorouracil. Expression of COX-2 showed cytoplasmic staining, not only in cancer cells but also in precancerous lesions such as metaplastic and adenomatous cells. We confirmed up-regulation of COX-2 in gastric cancer tissues compared with normal paired mucosa using Western blot analysis. There was no correlation between clinicopathological characteristics of gastric cancer patients and intensity of COX-2 protein expression. This study indicates that COX-2 protein over-expression may contribute to an early event of gastric cancer development, and it further suggests that selective inhibition of COX-2 may provide a chemopreventive effect against gastric carcinogenesis.
Insights
Cyclooxygenase-2 (COX-2) protein is over-expressed in gastric cancer tissues, suggesting it plays a role in early cancer development. Inhibiting COX-2 may offer a preventive strategy against gastric carcinogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastric adenocarcinoma is a prevalent malignancy with poorly understood molecular underpinnings.
- Nonsteroid anti-inflammatory drugs, particularly those inhibiting cyclooxygenase (COX) enzymes, have been linked to reduced colon cancer risk.
- COX-2, an isoform of COX, is implicated in inflammation and carcinogenesis, making its role in gastric cancer a key research area.
Purpose of the Study:
- To investigate the expression of COX-2 in human gastric carcinoma tissues.
- To determine the potential role of COX-2 in the development and progression of gastric cancer.
- To explore the implications of COX-2 inhibition for gastric cancer chemoprevention.
Main Methods:
- Immunohistochemical analysis of COX-2 expression in 104 human gastric carcinoma tissues and paired normal mucosa.
- Western blot analysis to confirm COX-2 up-regulation in gastric cancer tissues.
- Analysis of tissue specimens from surgically resected gastric adenocarcinoma patients.
Main Results:
- COX-2 protein expression was observed in the cytoplasm of gastric cancer cells, as well as in precancerous lesions (metaplastic and adenomatous cells).
- Western blot analysis confirmed significant up-regulation of COX-2 in gastric cancer tissues compared to normal mucosa.
- No correlation was found between the intensity of COX-2 protein expression and clinicopathological characteristics of the patients.
Conclusions:
- Over-expression of COX-2 protein appears to be an early event in the development of gastric cancer.
- The findings suggest that selective inhibition of COX-2 could be a potential chemopreventive strategy against gastric carcinogenesis.
- Targeting COX-2 may offer a novel therapeutic avenue for preventing the onset of gastric cancer.